Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

RCT (n=954) found those given lenvatinib reported nominally superior health related quality of life outcomes vs sorafenib, though differences were not clinically or statistically significant. Fatigue, pain and diarrhoea domain scores were statistically superior for lenvatinib.

Lancet Gastroenterology and Hepatology